Epidemiology
The Epidemiology group is interested in studying the patterns, causes and effects of neurocognitive disorders, in particular dementia, in elderly populations in Australia and internationally. Read more about the Epidemiology Group.
Genomics and Epigenomics
The Genetics and Epigenomics group has grown out of our interest in the genetics of brain ageing and age-related disease. Heritability studies suggest that there is a genetic component to most age-related traits. Read more about the Genomics and Epigenomics Group.
Neuroimaging
The Neuroimaging Laboratory (NiL) was established in 1991 in response to a need for the assessment of brain images, in order to improve our understanding of the brain in health and disease. Read more about the Neuroimaging Group.
Neuropsychiatry
The Neuropsychiatry Group is a collaborative group composed of staff from CHeBA and the Neuropsychiatric Institute (NPI). Read more about the Neuropsychiatry Group.
Neuropsychology
The Neuropsychology Group investigates cognitive changes associated with normal ageing and late-life disorders of cognition, to better understand the risk and preventive factors for age-related neurocognitive disorders. Read more about the Neuropsychology Group.
Risk Factors
The Risk Factors Group is interested in understanding and reducing the cognitive impacts of modifiable risk factors for dementia across the lifespan. Read more about the Risk Factors Group.
Molecular Biomarkers
The Molecular Biomarkers Group has a focus on identifying blood biomarkers and understanding mechanisms of neurodegenerative diseases of ageing, particularly the dementias, using techniques such as proteomics, metabolomics and mass spectrometry.
Read more about the Molecular Biomarkers Group.
Brain Ageing Research Laboratory (BARL)
The BARL aims to fully characterise potential biomarkers, developing tools to investigate in vivo metabolic and bioenergetic changes and correlate them with variable dementia metrics. It also aims to explore therapeutic strategies to attenuate cognitive decline and dementia pathology. Read more about the BARL.
